Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Lodge

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
European Journal of Pharmacology|June 2, 2019
Pharmacological characterizations of the 'legal high' fluorolintane and isomersJason Wallach, Tristan Colestock, Julià Agramunt, et al.
Neuropharmacology|June 5, 2012
Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPRHelen Sanger, Lydia Hanna, Ellen M Colvin, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 6, 2011
Study of novel selective mGlu2 agonist in the temporo-ammonic input to CA1 neurons reveals reduced mGlu2 receptor expression in a Wistar substrain with an anxiety-like phenotypeLaura Ceolin, Sriharsha Kantamneni, Gareth R I Barker, et al.
Neuropharmacology|April 2, 2013
Antagonists reversibly reverse chemical LTD induced by group I, group II and group III metabotropic glutamate receptorsDavid Lodge, Patrick Tidball, Marion S Mercier, et al.
Neuropharmacology|July 17, 2012
The NMDA receptor as a target for cognitive enhancementGraham L Collingridge, Arturas Volianskis, Neil Bannister, et al.
Nature Neuroscience|June 25, 2002
Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizuresIlse Smolders, Zuner A Bortolotto, Vernon R J Clarke, et al.
Neuropharmacology|September 16, 2008
ACET is a highly potent and specific kainate receptor antagonist: characterisation and effects on hippocampal mossy fibre functionSheila L Dargan, Vernon R J Clarke, Gregory M Alushin, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2005
Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 5Kumiko Takeuchi, Todd J Kohn, Nicholas A Honigschmidt, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 6, 2003
LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's diseaseTracey K Murray, Katherine Whalley, Christine S Robinson, et al.
JMIR Research Protocols|July 25, 2020
An Evaluation of Agreement of Breathing Rates Measured by a Novel Device, Manual Counting, and Other Techniques Used in Clinical Practice: Protocol for the Observational VENTILATE StudyMatthew T Jones, Emily Heiden, Carole Fogg, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
European Journal of Pharmacology|June 2, 2019
Pharmacological characterizations of the 'legal high' fluorolintane and isomersJason Wallach, Tristan Colestock, Julià Agramunt, et al.
Neuropharmacology|June 5, 2012
Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPRHelen Sanger, Lydia Hanna, Ellen M Colvin, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 6, 2011
Study of novel selective mGlu2 agonist in the temporo-ammonic input to CA1 neurons reveals reduced mGlu2 receptor expression in a Wistar substrain with an anxiety-like phenotypeLaura Ceolin, Sriharsha Kantamneni, Gareth R I Barker, et al.
Neuropharmacology|April 2, 2013
Antagonists reversibly reverse chemical LTD induced by group I, group II and group III metabotropic glutamate receptorsDavid Lodge, Patrick Tidball, Marion S Mercier, et al.
Neuropharmacology|July 17, 2012
The NMDA receptor as a target for cognitive enhancementGraham L Collingridge, Arturas Volianskis, Neil Bannister, et al.
Nature Neuroscience|June 25, 2002
Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizuresIlse Smolders, Zuner A Bortolotto, Vernon R J Clarke, et al.
Neuropharmacology|September 16, 2008
ACET is a highly potent and specific kainate receptor antagonist: characterisation and effects on hippocampal mossy fibre functionSheila L Dargan, Vernon R J Clarke, Gregory M Alushin, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2005
Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 5Kumiko Takeuchi, Todd J Kohn, Nicholas A Honigschmidt, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 6, 2003
LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's diseaseTracey K Murray, Katherine Whalley, Christine S Robinson, et al.
JMIR Research Protocols|July 25, 2020
An Evaluation of Agreement of Breathing Rates Measured by a Novel Device, Manual Counting, and Other Techniques Used in Clinical Practice: Protocol for the Observational VENTILATE StudyMatthew T Jones, Emily Heiden, Carole Fogg, et al.
Pageof 5